How psilocybin changes the brain

Psilocybin itself is largely inactive. Once ingested, the body rapidly converts it into psilocin, and it is psilocin that produces the psychedelic effect. Psilocin closely resembles serotonin, the neurotransmitter involved in mood, cognition and perception, and it acts primarily by stimulating serotonin receptors — above all the 5-HT2A receptor, which is densely concentrated in the cortex.

When psilocin activates these receptors on cortical neurons, it changes the pattern of activity across large parts of the brain. Rather than acting on a single region, it shifts how entire networks coordinate — which is why the effects touch perception, emotion, sense of self and thought all at once. The most consistent finding across brain-imaging studies is not that the brain does less, but that it connects differently.

Psilocybin is what pharmacologists call a prodrug — an inactive compound that the body transforms into an active one. After ingestion, enzymes (primarily alkaline phosphatase) strip a phosphate group from psilocybin through a process called dephosphorylation, producing psilocin. Psilocin is fat-soluble enough to cross the blood–brain barrier and reach the serotonin receptors where it does its work.

This conversion is why effects typically begin within 20 to 40 minutes rather than instantly. Psilocin has a relatively short half-life, which is part of why the acute experience generally lasts around four to six hours before the body clears it. The molecule leaves quickly — but, as the research on neuroplasticity below suggests, some of the changes it sets in motion can outlast the compound itself.

The 5-HT2A receptor is a specific type of serotonin receptor found in high density on pyramidal neurons in the cortex — the outer layer of the brain involved in higher-order thought, perception and self-reflection. Psilocin binds to and activates these receptors, and this single action appears to be the trigger for the entire psychedelic experience.

The evidence for this is unusually direct. When researchers give participants ketanserin, a drug that blocks the 5-HT2A receptor, before psilocybin, the psychedelic effects are largely abolished (Vollenweider and colleagues, and later Preller and colleagues). In other words: block this one receptor, and psilocybin can no longer change the brain in the way that produces the experience. That makes the 5-HT2A receptor the essential doorway through which psilocybin acts.

Yes — and this is the change that most defines psilocybin at the level of the whole brain. Under normal conditions, the brain is organised into relatively segregated networks, each handling particular functions and communicating mostly within themselves. After psilocybin, functional MRI studies show a marked increase in communication between networks that do not usually interact, alongside a loosening of the tight integrity within each network.

One influential analysis (Petri and colleagues, 2014) visualised this as a dramatic increase in novel connections across the brain — a far more interconnected, less compartmentalised pattern of activity. Carhart-Harris and colleagues have described the psychedelic state as a more "entropic" brain: more flexible, less constrained, and temporarily freed from some of its habitual routing. This global increase in connectivity is thought to underlie the fluid, boundary-dissolving quality of the experience.

The default mode network (DMN) is a set of connected brain regions most active when we are not focused on the outside world — during self-referential thought, rumination, mind-wandering, and the ongoing narrative of "me." It is often described as a neural correlate of the ego or the habitual sense of self, and it tends to be overactive and rigid in conditions such as depression and chronic anxiety.

Psilocybin reliably reduces activity and connectivity within the default mode network. Strikingly, the degree to which the DMN is disrupted correlates with the subjective experience of "ego dissolution" — the temporary softening of the boundary between self and world that many people describe. Researchers propose that quietening this network briefly interrupts the entrenched, self-reinforcing patterns of thought that keep people stuck, creating an opening for a different perspective to take hold.

A growing body of evidence suggests it does. Neuroplasticity is the brain’s capacity to reorganise itself by forming new connections between neurons. In preclinical studies, classic psychedelics including psilocybin have been shown to promote structural plasticity — Ly and colleagues (2018) found they increased the growth of dendritic spines and synapses, and coined the term "psychoplastogens" for compounds that do this. Related work points to increased signalling of BDNF, a protein that supports the growth and survival of neurons.

The practical implication is a window of enhanced plasticity — a period during and after the experience when the brain is unusually primed to form new connections and update old patterns. This is one of the most important ideas in the field, because it reframes the medicine as an opener of possibility rather than a fix in itself. The brain becomes more changeable; what happens in that window is what determines whether change actually takes root.

The leading framework linking brain changes to psychological change is the "relaxed beliefs under psychedelics" (REBUS) model, proposed by Carhart-Harris and Friston (2019). The brain is understood as a prediction machine that builds rigid expectations, or "priors," about the self and the world. In depression, anxiety and trauma, these priors can become overweighted and inflexible — the mind clings to negative certainties.

On this model, psilocybin temporarily relaxes those high-level priors, loosening their grip so that beliefs and emotional patterns become more open to revision. Combined with the increased plasticity and connectivity described above, this is thought to create a rare opportunity to update long-held patterns. Crucially, it is an opportunity, not a guarantee — which is precisely why psychological preparation and integration matter so much. The medicine loosens the pattern; the therapeutic work helps a healthier one settle in its place.

The acute subjective experience generally lasts around four to six hours, and measures of global connectivity return toward baseline as the psilocin clears — within roughly a day. But the brain changes do not necessarily end when the experience does. The window of heightened neuroplasticity is thought to remain open for a period afterwards, and several imaging studies have detected lingering effects on brain function well beyond the acute phase.

For example, Daws and colleagues (2022) reported increased brain network flexibility and reduced default-mode "modularity" that was still measurable around three weeks after treatment in people with depression, and correlated with clinical improvement. The emerging picture is of a short, intense acute effect followed by a longer tail of increased plasticity — a reason integration is best begun soon, while the brain is still unusually open to change.

Psilocybin has low physiological toxicity, is not considered neurotoxic, and does not produce the compulsive use or dependence associated with addictive drugs — reviews of its pharmacology consistently place it among the lowest-harm psychoactive substances on physiological measures. That said, "safe for the brain" is not the same as "safe for everyone in every context." The real risks with psilocybin are largely psychological rather than neurological.

A personal or family history of psychosis or bipolar disorder, certain cardiac conditions, and some medications are genuine contraindications, and a difficult experience without adequate support can be destabilising. This is why safety comes from the structure around the medicine rather than the molecule itself: thorough medical and psychological screening, trained supervision throughout the session, a controlled setting, and integration afterwards. No responsible program administers psilocybin without proper screening first.

The therapeutic research is genuinely promising but still early-stage. In a Johns Hopkins trial (Davis and colleagues, JAMA Psychiatry, 2021), 71% of participants showed a clinically significant response and 54% met criteria for remission from major depression four weeks after two supported psilocybin sessions. A head-to-head study at Imperial College London (Carhart-Harris and colleagues, New England Journal of Medicine, 2021) found psilocybin performed at least as well as the SSRI escitalopram, and the largest trial to date — a Phase 2b study of 233 people with treatment-resistant depression (Goodwin and colleagues, NEJM, 2022) — found a single 25mg dose significantly reduced symptoms at three weeks.

These findings map onto the brain science: reduced default mode network rigidity, increased connectivity, and a plasticity window that supports lasting change when paired with psychological support. But psilocybin is not yet a licensed medicine in most countries, larger Phase 3 trials are ongoing, and the honest framing — the one that governs our clinical practice — is real promise held alongside genuine caution. The neuroscience explains why this medicine is so interesting; it does not replace careful clinical judgement about whether it is right for a given person.